Acta Haematologica

Original Paper

Hydroxyurea Increases Plasma Concentrations of Microparticles and Reduces Coagulation Activation and Fibrinolysis in Patients with Sickle Cell Anemia

Brunetta D.M.a · De Santis G.C.a · Silva-Pinto A.C.a · Oliveira de Oliveira L.C.a, b · Covas D.T.a, b

Author affiliations

aCenter for Cell-Based Therapy and bHematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil

Keywords: HemostasisHydroxyureaMicroparticlesSickle cell anemia

Related Articles for ""
Acta Haematol 2015;133:287-294
https://doi.org/10.1159/000362148

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 23, 2013
Accepted: March 10, 2014
Published online: December 02, 2014
Issue release date: April 2015

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Abstract

Microparticles (MPs) are present in healthy subjects and their concentration increases in patients at high risk of thrombosis. We evaluated 10 patients with sickle cell anemia (SCA) treated with hydroxyurea (HU) and 13 SCA patients without this treatment. MP concentrations were determined by flow cytometry. Coagulation was evaluated using the thrombin-antithrombin complex (TAT) and D-dimers. Total MP concentrations were increased in the HU-treated group (265 × 106/ml vs. 67.45 × 106/ml; p = 0.0026), as well as MPs derived from RBC (67.83 × 106/ml vs. 26.31 × 106/ml; p = 0.05), monocytes (51.31 × 106/ml vs. 9.03 × 106/ml; p = 0.0084), monocytes with tissue factor (TF) expression (2.27 × 106/ml vs. 0.27 × 106/ml; p = 0.0058), endothelium (49.42 × 106/ml vs. 7.23 × 106/ml; p = 0.007) and endothelium with TF (1.42 × 106/ml vs. 0.26 × 106/ml; p = 0.0043). Furthermore, the concentrations of TAT (7.56 vs. 10.98 µg/l; p = 0.014) and D-dimers (0.65 vs. 1.29 µg/ml; p = 0.007) were reduced with HU. The MP elevation may suggest a direct cytotoxic effect of HU. Another explanation is a cell surface increase secondary to a megaloblastic process, resulting in increased vesicle release. In our opinion, the known benefits of HU on SCA patients, along with the reduction in coagulation activation, surpass its potential detrimental effect on MPs. Future studies should elucidate the role of MPs and demonstrate their significance in different contexts. © 2014 S. Karger AG, Basel

© 2014 S. Karger AG, Basel



Related Articles:

References

  1. Ataga KI, Key NS: Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007, pp 91-96.
    External Resources
  2. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, Sohier C, Hinderliter A, Parise LV, Orringer EP: Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20-26.
    External Resources
  3. Prengler M, Pavlakis SG, Prohovnik I, Adams RJ: Sickle cell disease: the neurological complications. Ann Neurol 2002;51:543-552.
    External Resources
  4. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD: Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001;125:1436-1441.
    External Resources
  5. Tomer A, Harker LA, Kasey S, Eckman JR: Thrombogenesis in sickle cell disease. J Lab Clin Med 2001;137:398-407.
    External Resources
  6. Francis RB Jr: Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis 1991;2:341-353.
    External Resources
  7. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Zuckerman L, Schlegel R, Williamson P: Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med 1999;134:352-362.
    External Resources
  8. Allan D, Limbrick AR, Thomas P, Westerman MP: Microvesicles from sickle erythrocytes and their relation to irreversible sickling. Br J Haematol 1981;47:383-390.
    External Resources
  9. Allan D, Limbrick AR, Thomas P, Westerman MP: Release of spectrin-free spicules on reoxygenation of sickled erythrocytes. Nature 1982;295:612-613.
    External Resources
  10. Key NS, Kwaan HC: Microparticles in thrombosis and hemostasis. Semin Thromb Hemost 2010;36:805-806.
    External Resources
  11. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-1132.
    External Resources
  12. Boulanger CM: Microparticles, vascular function and hypertension. Curr Opin Nephrol Hypertens 2010;19:177-180.
    External Resources
  13. Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A: Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011;106:310-321.
    External Resources
  14. Goichot B, Grunebaum L, Desprez D, Vinzio S, Meyer L, Schlienger JL, Lessard M, Simon C: Circulating procoagulant microparticles in obesity. Diabetes Metab 2006;32:82-85.
    External Resources
  15. Nomura S: Statin and endothelial cell-derived microparticles. Thromb Haemost 2008;100:377-378.
    External Resources
  16. De Franceschi L, Cappellini MD, Olivieri O: Thrombosis and sickle cell disease. Semin Thromb Hemost 2011;37:226-236.
    External Resources
  17. Ataga KI, Orringer EP: Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003;115:721-728.
    External Resources
  18. Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 2010;376:2018-2031.
    External Resources
  19. Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
    External Resources
  20. Aslan M, Freeman BA: Redox-dependent impairment of vascular function in sickle cell disease. Free Radic Biol Med 2007;43:1469-1483.
    External Resources
  21. Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, Koopmeiners L, Key NS, Hebbel RP: Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood 2003;102:2678-2683.
    External Resources
  22. Westerman M, Pizzey A, Hirschman J, Cerino M, Weil-Weiner Y, Ramotar P, Eze A, Lawrie A, Purdy G, Mackie I, Porter J: Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008;142:126-135.
    External Resources
  23. Wun T, Paglieroni T, Rangaswami A, Franklin PH, Welborn J, Cheung A, Tablin F: Platelet activation in patients with sickle cell disease. Br J Haematol 1998;100:741-749.
    External Resources
  24. van Tits LJ, van Heerde WL, Landburg PP, Boderie MJ, Muskiet FA, Jacobs N, Duits AJ, Schnog JB: Plasma annexin A5 and microparticle phosphatidylserine levels are elevated in sickle cell disease and increase further during painful crisis. Biochem Biophys Res Commun 2009;390:161-164.
    External Resources
  25. Noubouossie DC, Le PQ, Rozen L, Debaugnies F, Ferster A, Demulder A: Evaluation of the procoagulant activity of endogenous phospholipids in the platelet-free plasma of children with sickle cell disease using functional assays. Thromb Res 2012;130:259-264.
    External Resources
  26. Gerotziafas GT, Van Dreden P, Chaari M, Galea V, Khaterchi A, Lionnet F, Stankovic-Stojanovic K, Blanc-Brude O, Woodhams B, Maier-Redelsperger M, Girot R, Hatmi M, Elalamy I: The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb Haemost 2012;107:1044-1052.
    External Resources
  27. Nebor D, Romana M, Santiago R, Vachiery N, Picot J, Broquere C, Chaar V, Doumdo L, Odievre MH, Benkerrou M, Elion J: Fetal hemoglobin and hydroxycarbamide modulate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica 2013;98:862-867.
    External Resources
  28. Lofvenberg E, Nilsson T, Wahlin A, Jacobsson L: Hydroxyurea treatment of myeloproliferative disorders. Macro-megaloblastic blood and bone marrow changes. Acta Med Scand 1987;222:169-174.
    External Resources
  29. Seki JT, Al-Omar HM, Amato D, Sutton DM: Acute tumor lysis syndrome secondary to hydroxyurea in acute myeloid leukemia. Ann Pharmacother 2003;37:675-678.
    External Resources
  30. Kramer OH, Knauer SK, Zimmermann D, Stauber RH, Heinzel T: Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene 2008;27:732-740.
    External Resources
  31. Pearson HA, Spencer RP, Cornelius EA: Functional asplenia in sickle-cell anemia. N Engl J Med 1969;281:923-926.
    External Resources
  32. Koc A, Gumruk F, Gurgey A: The effect of hydroxyurea on the coagulation system in sickle cell anemia and beta-thalassemia intermedia patients: a preliminary study. Pediatr Hematol Oncol 2003;20:429-434.
    External Resources
  33. van Beers EJ, Peters M, Biemond BJ: Pathophysiology and treatment of sickle-cell disease (in Dutch). Ned Tijdschr Geneeskd 2005;149:1144-1149.
    External Resources
  34. Qari MH, Dier U, Mousa SA: Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease. Clin Appl Thromb Hemost 2012;18:195-200.
    External Resources
  35. Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, Zielinski C, Pabinger I: Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 2012;10:1363-1370.
    External Resources
  36. Kushak RI, Nestoridi E, Lambert J, Selig MK, Ingelfinger JR, Grabowski EF: Detached endothelial cells and microparticles as sources of tissue factor activity. Thromb Res 2005;116:409-419.
    External Resources
  37. Aharon A, Brenner B: Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009;22:61-69.
    External Resources
  38. Perez-Casal M, Downey C, Fukudome K, Marx G, Toh CH: Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood 2005;105:1515-1522.
    External Resources
  39. Lacroix R, Dignat-George F: Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res 2012;129(suppl 2):S27-S29.
    External Resources
  40. Mostefai HA, Meziani F, Mastronardi ML, Agouni A, Heymes C, Sargentini C, Asfar P, Martinez MC, Andriantsitohaina R: Circulating microparticles from patients with septic shock exert a protective role in vascular function. Am J Respir Crit Care Med 2008;178:1148-1155.
    External Resources
  41. Guervilly C, Lacroix R, Forel JM, Roch A, Camoin-Jau L, Papazian L, Dignat-George F: High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care 2011;15:R31.
    External Resources
  42. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F: Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010;8:2571-2574.
    External Resources
  43. Lacroix R, Judicone C, Mooberry M, Boucekine M, Key NS, Dignat-George F: Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2013, Epub ahead of print.
    External Resources
  44. Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM: Pre-analytical issues in the measurement of circulating microparticles: Current recommendations and pending questions. J Thromb Haemost 2013;11:693-696.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: July 23, 2013
Accepted: March 10, 2014
Published online: December 02, 2014
Issue release date: April 2015

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 0

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2015, Vol.133, No. 3

April 2015

Article

Recommend This
TOP